A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance

Antiviral Research

Volumn 148, Issue , 2017, Pages 1-4

  Chou, Sunwen ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Antiviral drug resistance; Cytomegalovirus; Letermovir; Terminase

Indexed keywords

HUMAN CYTOMEGALOVIRUS TERMINASE COMPLEX; LETERMOVIR; UNCLASSIFIED DRUG; VIRUS ENZYME; ACETIC ACID DERIVATIVE; ANTIVIRUS AGENT; DEOXYRIBONUCLEASE; MULTIPROTEIN COMPLEX; QUINAZOLINE DERIVATIVE; TERMINASE; VIRAL PROTEIN;

AMINO ACID SUBSTITUTION; ARTICLE; CODON; CONTROLLED STUDY; EC50; GENOTYPE; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; MUTATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; VIRUS RESISTANCE; ANTAGONISTS AND INHIBITORS; ANTIVIRAL RESISTANCE; CELL CULTURE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG EFFECT; ENZYMOLOGY; FIBROBLAST; GENETICS; METABOLISM; VIROLOGY; VIRUS GENE;

ACETATES; ANTIVIRAL AGENTS; CELLS, CULTURED; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, VIRAL; ENDODEOXYRIBONUCLEASES; FIBROBLASTS; GENES, VIRAL; HUMANS; MULTIPROTEIN COMPLEXES; MUTATION; QUINAZOLINES; VIRAL PROTEINS;

EID: 85032445891     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2017.10.019     Document Type: Article

References (10)

1. Bogner, E., Human cytomegalovirus packaging: an update on structure-function relationships. Future Virol. 5 (2010), 397–404.
2. Borst, E.M., Kleine-Albers, J., Gabaev, I., Babic, M., Wagner, K., Binz, A., Degenhardt, I., Kalesse, M., Jonjic, S., Bauerfeind, R., Messerle, M., The human cytomegalovirus UL51 protein is essential for viral genome cleavage-packaging and interacts with the terminase subunits pUL56 and pUL89. J. Virol. 87 (2013), 1720–1732.
3. Chou, S., Rapid in vitro evolution of human cytomegalovirus UL56 mutations that confer letermovir resistance. Antimicrob. Agents Chemother. 59 (2015), 6588–6593.
4. Chou, S., Comparison of cytomegalovirus terminase gene mutations selected after exposure to three distinct inhibitor compounds. Antimicrob. Agents Chemother. 61 (2017), e01325–e013217, 10.1128/AAC.01325-01317.
5. Chou, S., Ercolani, R.J., Vanarsdall, A.L., Differentiated levels of ganciclovir resistance conferred by mutations at codons 591 to 603 of the cytomegalovirus UL97 kinase gene. J. Clin. Microbiol. 55 (2017), 2098–2104.
6. Goldner, T., Hempel, C., Ruebsamen-Schaeff, H., Zimmermann, H., Lischka, P., Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. Antimicrob. Agents Chemother. 58 (2014), 610–613.
7. Lischka, P., Michel, D., Zimmermann, H., Characterization of cytomegalovirus breakthrough events in a Phase 2 prophylaxis trial of letermovir (AIC246, MK 8228). J. Infect. Dis. 213 (2016), 23–30.
8. Neuber, S., Wagner, K., Goldner, T., Lischka, P., Steinbrueck, L., Messerle, M., Borst, E.M., Mutual interplay between the human cytomegalovirus terminase subunits pUL51, pUL56, and pUL89 promotes terminase complex formation. J. Virol. 91 (2017), e02384–e023816, 10.1128/JVI.02384-02316.
9. Tischer, B.K., Smith, G.A., Osterrieder, N., En passant mutagenesis: a two step markerless red recombination system. Methods Mol. Biol. 634 (2010), 421–430.
10. Wang, J.B., Zhu, Y., McVoy, M.A., Parris, D.S., Changes in subcellular localization reveal interactions between human cytomegalovirus terminase subunits. Virol. J., 9, 2012, 315.